METRONIDAZOLE tablet

País: Estats Units

Idioma: anglès

Font: NLM (National Library of Medicine)

ingredients actius:

METRONIDAZOLE (UNII: 140QMO216E) (METRONIDAZOLE - UNII:140QMO216E)

Disponible des:

NCS HealthCare of KY, Inc dba Vangard Labs

Designació comuna internacional (DCI):

METRONIDAZOLE

Composición:

METRONIDAZOLE 500 mg

Vía de administración:

ORAL

tipo de receta:

PRESCRIPTION DRUG

indicaciones terapéuticas:

Metronidazole, USP is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Metronidazole, USP is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.  Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted t

Resumen del producto:

Metronidazole Tablets USP are available as follows: 250 mg - White, round, convex, unscored tablets debossed on one side with PLIVA 333 . 500 mg - White, oblong, convex, unscored tablets debossed on one side with PLIVA 334 . Available in blistercards of 30. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. PROTECT FROM LIGHT Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. ______________________________________________________________________________ 1. Proposed standard: PSM-11-Proposed Reference Dilution Procedure for Antimicrobic Susceptibility Testing of Anaerobic Bacteria, National Committee for Clinical Laboratory Standards; and Sutter, et al.: Collaborative Evaluation of a Proposed Reference Dilution Method of Susceptibility Testing of Anaerobic Bacteria, Antimicrob. Agents Chemother. 16:495-502 (Oct.) 1979; and Tally, et al.: In Vitro Activity of Thienamycin, Antimicrob. Agents Chemother. 14:436-438 (Sept.) 1978. 2. Ralph, E.D., and Kirby, W.M.M.: Bioassay of Metronidazole With Either Anaerobic or Aerobic Incubation, J. Infect. Dis. 132:587-591 (Nov.) 1975; or Gulaid, et al.: Determination of Metronidazole and Its Major Metabolites in Biological Fluids by High Pressure Liquid Chromatography, Br. J. Clin. Pharmacol. 6:430-432, 1978. Manufactured In Czech Republic By: TEVA CZECH INDUSTRIES s.r.o. Opava-Komarov, Czech Republic Manufactured For: TEVA PHARMACEUTICALS USA Sellersville, PA 18960 Rev. A 6/2011

Estat d'Autorització:

Abbreviated New Drug Application

Fitxa tècnica

METRONIDAZOLE- METRONIDAZOLE TABLET
NCS HEALTHCARE OF KY, INC DBA VANGARD LABS
----------
REV. A 6/2011
RX ONLY
TO REDUCE THE DEVELOPMENT OF DRUG-RESISTANT BACTERIA AND MAINTAIN THE
EFFECTIVENESS OF
METRONIDAZOLE AND OTHER ANTIBACTERIAL DRUGS, METRONIDAZOLE SHOULD BE
USED ONLY TO TREAT OR
PREVENT INFECTIONS THAT ARE PROVEN OR STRONGLY SUSPECTED TO BE CAUSED
BY BACTERIA.
WARNING: Metronidazole has been shown to be carcinogenic in mice and
rats. (See
PRECAUTIONS.) Unnecessary use of the drug should be avoided. Its use
should be reserved
for the conditions described in the INDICATIONS AND USAGE section
below.
DESCRIPTION
Metronidazole, USP is an oral synthetic antiprotozoal and
antibacterial agent, 1 (β-hydroxyethyl)-2-
methyl-5-nitroimidazole, which has the following structural formula:
C H N O M.W. 171.15
Each tablet for oral administration contains 250 mg or 500 mg of
metronidazole, USP. Inactive
ingredients include microcrystalline cellulose, crospovidone,
colloidal silicon dioxide and
hydrogenated vegetable oil.
CLINICAL PHARMACOLOGY
Disposition of metronidazole in the body is similar for both oral and
intravenous dosage forms, with an
average elimination half-life in healthy humans of eight hours.
The major route of elimination of metronidazole and its metabolites is
via the urine (60 to 80% of the
dose), with fecal excretion accounting for 6 to 15% of the dose. The
metabolites that appear in the urine
result primarily from side-chain oxidation
[1-(β-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole and
2-methyl-5-nitroimidazole-1-yl-acetic acid] and glucuronide
conjugation, with unchanged metronidazole
accounting for approximately 20% of the total. Renal clearance of
metronidazole is approximately 10
mL/min/1.73 m2.
Metronidazole is the major component appearing in the plasma, with
lesser quantities of the 2-
hydroxymethyl metabolite also being present. Less than 20% of the
circulating metronidazole is bound
to plasma proteins. Both the parent compound and the metabolite
possess in vitro bactericidal activity